Significance of Asymmetric Basal Posterior Wall Thinning in Patients With Cardiac Fabry's Disease

American Journal of Cardiology

Volumn 99, Issue 2, 2007, Pages 261-263

  Kawano, Makoto ^a   Takenaka, Toshihiro ^a   Otsuji, Yutaka ^a   Teraguchi, Hiroyuki ^a   Yoshifuku, Shiro ^a   Yuasa, Toshinori ^a   Yu, Bo ^a   Miyata, Masaaki ^a   Hamasaki, Shuichi ^a   Minagoe, Shinichi ^a   Kanmura, Yuichi ^a   Tei, Chuwa ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FABRY DISEASE; FEMALE; HEART DEATH; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HUMAN; MALE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY, DOPPLER; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME;

EID: 33846082470     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.088     Document Type: Article

References (18)

1. Desnick R.J., Ioannou Y.A., and Eng C.M. α-Galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Basis of Inherited Disease. 8th Ed. Vol 3 (2001), McGraw-Hill, New York, New York 3733-3774
2. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., and Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138 (2003) 338-346
3. Elleder M., Bradová V., Šmíd F., Budešíinsky M., Harzer K., Kustermann-Kuhn B., Ledvinova J., Belohlavek V.K., and Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417 (1990) 449-455
4. von Scheidt W., Eng C.M., Fitzmaurice T.F., Erdmann E., Hübner G., Olsen E.G.J., Christomanou H., Kandolf R., Bishop D.F., and Desnick R.J. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324 (1991) 395-399
5. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H., and Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 (1995) 288-293
6. Sachdev B., Takenaka T., Teraguchi H., Tei C., Lee P., McKenna W.J., and Elliott P.M. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002) 1407-1411
7. Yoshitama T., Nakao S., Takenaka T., Teraguchi H., Sasaki T., Kodama C., Tanaka A., Kisanuki A., and Tei C. Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry's disease. Am J Cardiol 87 (2001) 71-75
8. Henry W.L., Clark C.E., and Epstein S.E. Asymmetric septal hypertrophy: echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation 47 (1973) 225-233
9. Cohen G.I., Pietrolungo J.F., Thomas J.D., and Klein A.L. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 27 (1996) 1753-1760
10. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 26 (1995) 135-136
11. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
12. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow E., Liang T.J., Kreps C., et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97 (2000) 365-370
13. Takenaka T., Murray G.J., Qin G., Quirk J.M., Ohshima T., Qasba P., Clark K., Kulkarni A.B., Brady R.O., and Medin J.A. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A 97 (2000) 7515-7520
14. Yoshimitsu M., Sato T., Tao K., Walia J.S., Rasaiah V.I., Sleep G.T., Murray G.J., Poeppl A.G., Underwood J., West L., et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101 (2004) 16909-16914
15. Tei C., Dujardin K.S., Hodge D.O., Kyle R.A., Tajik A.J., and Seward J.B. Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol 28 (1996) 658-664
16. Bass J.L., Shrivastava S., Grabowski G.A., Desnick R.J., and Moller J.H. The M-mode echocardiogram in Fabry's disease. Am Heart J 100 (1980) 807-812
17. Moon J.C.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., Leed P.J., and Elliott P.M. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (2003) 2151-2155
18. Pieroni M., Chimenti C., Ricci R., Sale P., Russo M.A., and Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107 (2003) 1978-1984